Pharmafile Logo

Janet Woodcock

- PMLiVE

bluebird bio shares therapy updates for 2022

The company provided information for its first two gene therapies and its lovo-cel BLA submission for sickle cell disease

- PMLiVE

Results from trial show Eli Lilly’s COVID-19 drug improves survival rates

The RECOVERY trial is the biggest study of COVID-19 treatments in the world, involving more than 47,000 participants in the UK

- PMLiVE

FDA issues final guidances for clinical cancer trials

The FDA is working to address inequities, target the right treatments to the right patients and speed progress against the most deadly and rare cancers

- PMLiVE

Verily Life Science signs new contract with Oncimmune for long COVID study

The project will analyse potential patterns of autoantibodies, which are associated with developing long COVID

- PMLiVE

Janssen and Legend Biotech’s Carvykti receives FDA approval for patients with relapsed or refractory multiple myeloma

In the study, 98% of patients with relapsed or refractory multiple myeloma responded to a one-off treatment of the drug

- PMLiVE

England to end COVID-19 isolation laws and mass free testing

From 24 February, all COVID-19 restrictions will end in England and from 1 April, all free mass testing will finish

- PMLiVE

COVID-19 booster to be made available to those over 75 and high risk adults and children

Around 7.2 million people living in the UK aged over 75 – having already had their primary course of COVID-19 vaccines – will be eligible for the booster

Biomarin

FDA keeps BioMarin’s gene therapy for phenylketonuria on hold

The decision follows data suggesting BioMarin’s experimental gene therapies may have the potential to progress cancers

- PMLiVE

Eli Lilly’s Omicron drug treatment gets emergency use authorisation from FDA

The drug can be used to treat adults with mild-to-moderate COVID-19, and children aged 12 or older, in specific emergency cases in non-hospital settings

- PMLiVE

WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

The prequalification confirms the treatment meets WHO’s standards for quality, effectiveness and safety

- PMLiVE

FDA accepts Priority Review for Dupixent in children with moderate-to-severe atopic dermatitis

If approved, Dupixent would be the first biologic treatment available in the US for children aged six months to five years with the skin condition

- PMLiVE

Merck and Ridgeback fulfil US deal for molnupiravir

Over three million courses of the investigational oral antiviral COVID-19 treatment have been supplied

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links